Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17

Xing-Cheng Wu, Wei-Gang Yan, Zhi-Gang Ji, Guo-Yang Zheng, Guang-Hua Liu

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, China

Submitted: 25 December 2018
Accepted: 20 April 2019

Arch Med Sci
DOI: https://doi.org/10.5114/aoms.2019.85653

Copyright © 2019 Termedia & Banach

Abstract

Introduction: Accumulating evidence has revealed the critical roles of long noncoding RNAs (lncRNAs) in various cancers. LncRNA SNHG20 has been shown to be a cancer-associated lncRNA in several cancers with diverse mechanisms. However, the clinical references, biological roles, and mechanisms of action of SNHG20 in prostate cancer (PCa) are still unclear.

Material and methods: The expression of SNHG20 in PCa tissues and cell lines was detected by RT-qPCR. The correlations between SNHG20 expression and clinicopathological features were analyzed by \( \chi^2 \) test. The roles of SNHG20 in PCa cell proliferation and migration were detected by CCK-8, EdU incorporation, and transwell assays. The regulatory mechanisms of SNHG20 on DDX17 were detected by dual luciferase reporter assay, RT-qPCR, and western blot.

Results: SNHG20 is highly expressed in PCa tissues and cell lines. High expression of SNHG20 is positively correlated with high Gleason score and advanced tumor stage. Functional experiments revealed that overexpression of SNHG20 promotes PCa cell proliferation and migration. SNHG20 knockdown represses PCa cell proliferation and migration. Mechanistically, SNHG20 was verified to act as a competing endogenous RNA (ceRNA) to upregulate DDX17. DDX17 is also highly expressed and has oncogenic roles in PCa. Furthermore, the expression of DDX17 is significantly positively correlated with that of SNHG20 in PCa tissues. Depletion of DDX17 reverses the oncogenic roles of SNHG20 in PCa.

Conclusions: These data showed that SNHG20 promotes PCa cell proliferation and migration via acting as a ceRNA to upregulate DDX17. This study also suggested that SNHG20 may be a potential novel therapeutic target for PCa.

Key words: prostate cancer, long noncoding RNA, competing endogenous RNA, DDX17, proliferation, migration.

Introduction

Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer-related death in men worldwide [1]. The estimated number of new PCa cases is 1,276,106 and the estimated number of deaths caused by PCa is 358,989 in 2018 worldwide [1]. With the development of the economy, the incidence of PCa is obviously increasing, particularly in developing countries [2]. Due to the great advances of therapeutic strategies, including surgery, radiotherapy, molecular targeted therapy, and immunotherapy, the survival of most early PCa patients is relatively
good [3]. However, the efficiencies of therapies for PCa diagnosed at advanced stages with metastases or castration resistance are only palliative [4, 5]. Thus, further revealing the underlying molecular mechanisms and identifying novel therapeutic targets for aggressive PCa are urgent [6].

Increasing evidence has shown that most of the human transcriptome consists of non-coding RNAs, but not mRNAs [7]. Long noncoding RNAs (lncRNAs) are a class of regulatory non-coding RNAs with no protein coding potential and longer than 200 nucleotides in length [8, 9]. Relative to the 21,000 genes, more than 58,000 lncRNAs have been identified in humans [7]. Among these lncRNAs, many were further found to be deregulated in various diseases, including cancers [10–14]. Among these differently expressed lncRNAs, some were further verified to have important roles in a variety of pathophysiological statuses [15–21]. The lncRNAs were reported to regulate the various biological behaviors of cancer cells, including proliferation, cell cycle, apoptosis, senescence, migration, invasion, growth, metastasis, drug resistance, and so on [22–26].

The mechanisms of action of lncRNAs are complex and diverse. They could directly interact with proteins, mRNAs, microRNAs (miRNAs) and/or DNAs, and further change the locations, expressions and/or functions of their interacting partners [27–29]. Several lncRNAs were revealed to competitively sponge common miRNAs and relieve the suppressive roles of miRNAs on their targets [30–32]. Therefore, these lncRNAs upregulate the expression of targets of common miRNAs [33, 34]. These lncRNAs were classified as competing endogenous RNAs (ceRNAs) [35, 36].

LncRNA SNHG20 was reported to be highly expressed and predict poor prognosis in colorectal cancer, hepatocellular carcinoma, gastric cancer, osteosarcoma, cervical cancer, and non-small cell lung cancer [37–42]. SNHG20 was also revealed to generally play oncogenic roles in these cancers via different mechanisms. SNHG20 upregulates ZFX expression via sponging miR-495-3p in gastric cancer [39]. SNHG20 induced epithelial-mesenchymal transition-associated genes in osteosarcoma [40]. SNHG20 upregulates ADAM10 expression via sponging miR-140-5p in cervical cancer [41]. SNHG20 epigenetically silences p21 in non-small cell lung cancer [42]. These different mechanisms of action of SNHG20 in different cancers implied the disease-specific function manners of SNHG20 and the need to further investigate the expression, functions, and mechanisms of action of SNHG20 in other cancers.

Thus, we further explored the expression pattern, roles, and mechanisms of action of SNHG20 in PCa. Our data revealed that SNHG20 also functions as an oncogene in PCa. Furthermore, we identified a novel mechanism of action of SNHG20 in PCa.

Material and methods

Clinical samples

The PCa tissues and adjacent noncancerous tissues were collected from 68 PCa patients who underwent tumor resection in Peking Union Medical College Hospital (Beijing, China) with written informed consent. All clinical samples were immediately frozen in liquid nitrogen for further use. The study was carried out in accordance with the Helsinki Declaration and was approved by the Ethics Committee of Peking Union Medical College Hospital.

Cell culture

The human PCa cell lines PC3 and DU145 and the normal prostate epithelial cell line RWPE-1 were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA). RWPE-1 cells were maintained in Keratinocyte Serum Free Medium (KSFM) kit (Invitrogen, Carlsbad, CA, USA). PC3 cells were maintained in F12K Medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). DU145 cells were maintained in Eagle’s Minimum Essential Medium (Invitrogen) supplemented with 10% FBS (Invitrogen). The cells were incubated in a humidified atmosphere at 37°C with 5% CO2.

Vectors construction

SNHG20 full-length sequences were PCR-amplified with the Thermo Scientific Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific, Inc., Rockford, IL, USA) and the primers 5′-CGGGATCCAGTGCTGACCGAGCTACTT-3′ (sense) and 5′-GGATTGGATCAAAAGTGTTTAATTCCA-3′ (antisense). The PCR products were then inserted into the BamH I and EcoR I sites of pcDNA3.1(+) vector (Invitrogen), named as pcDNA-SNHG20. One pair of cDNA oligonucleotides specifically inhibiting SNHG20 were synthesized and inserted into the GenePharma supersilencing shRNA expression vector pGPU6/Neo (GenePharma, Shanghai, China). The target site is 5′-GCCTAGGATCATCCAGGTTGG-3′. The DDX17 overexpression vector was purchased from FulenGen (Guangzhou, China) (Catalog, EX-Z3245-M02). DDX17 specific shRNA expression vector was purchased from FulenGen (Guangzhou, China) (Catalog, HSH000626-nU6). The 3′UTR of DDX17 was PCR-amplified with the Thermo Scientific Phusion Flash High-Fidelity PCR Master Mix and the primers 5′-CGAGCTCCACCTCAAATGGTACT-3′.
(sense) and 5′-GCTCTAGAGAAAACAGAGATGG-TATC-3′ (antisense). The PCR products were then inserted into the Sac I and Xba I sites of pmirGLO vector (Promega, Madison, WI, USA), named as pmirGLO-DDX17.

Stable cell lines construction

In order to construct SNHG20 stably overexpressed PCa cells, pcDNA-SNHG20 was transfected into PC3 and DU145 cells with Lipofectamine 3000 (Invitrogen) in accordance with the protocol. Forty-eight hours after transfection, PC3 and DU145 cells were treated and selected with puromycin for four weeks. In order to construct SNHG20 stably depleted PCa cells, SNHG20 specific shRNA was transfected into PC3 and DU145 cells with Lipofectamine 3000 (Invitrogen). Seventy-two h after transfection, PC3 and DU145 cells were treated and selected with puromycin for 4 weeks. In order to construct DDX17 stably overexpressed PCa cells, pcDNA-DDX17 was transfected into PC3 cells with Lipofectamine 3000 (Invitrogen). Forty-eight hours after transfection, PC3 cells were treated and selected with puromycin for 4 weeks. In order to construct DDX17 stably depleted PCa cells, DDX17 specific shRNA was transfected into PC3 and DU145 cells with Lipofectamine 3000 (Invitrogen). Seventy-two h after transfection, PC3 and DU145 cells were treated and selected with puromycin for 4 weeks.

RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from indicated tissues and cells with the TRIzol Regent (Invitrogen) in accordance with the protocol. The RNA quality and concentration were determined using NanoDrop ND-2000/2000C. Next, equal quantification of RNA was subjected to reverse transcription with the M-MLV Reverse Transcriptase (Promega) in accordance with the protocol. Subsequently, the cDNA was used as a template for real-time quantitative polymerase chain reaction (RT-qPCR) with SYBR Green Master Mix (Takara, Dalian, China) and ND-2000/2000C. Next, equal quantification of RNA expression was normalized to GAPDH and calculated using the 2−ΔΔCt method.

Western blot

Cell lysates were prepared from indicated PCa cells with the RIPA lysis buffer (Beyotime, Shanghai, China). Protein concentration was measured using BCA Protein Assay Kit (Beyotime) in accordance with the protocol. Subsequently, proteins were fractionated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto 0.45 μm polyvinylidene fluoride (PVDF) membrane (Millipore, Boston, MA, USA). After being blocked in 5% non-fat milk for 2 h at room temperature, the membranes were incubated with primary antibodies against DDX17 (Abcam, Hong Kong, China) or GAPDH (Affinity, Changzhou, China) overnight at 4°C. After being washed three times, the membranes were incubated with a HRP-conjugated secondary antibody (Beyotime) and detected with an ECL-Plus kit (Amersham Biosciences, Piscataway, NJ, USA).

Cell proliferation assays

Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and ethynyl deoxyuridine (EdU) incorporation assays. For CCK-8 assay, indicated PCa cells were plated at 2 × 104 cells/well into 96-well plates. After incubation for the indicated time, CCK-8 solution (Dojindo Laboratories, Kumamoto, Japan) was added into the wells. Optical density (OD) values at 450 nm at indicated time points were detected using an automatic enzyme-linked immune detector. EdU incorporation assay was carried out using the Cell-Light EdU Apollo 643 In Vitro Imaging Kit (RiboBio, Guangzhou, China) following the protocol. Results were detected with a Zeiss fluorescence photomicroscope (Carl Zeiss, Oberkochen, Germany) and counted based on five randomly chosen visual fields.

Transwell migration assay

Indicated PCa cells resuspended in serum-free medium were plated at 2 × 105 cells/well into 24-well transwell chambers (BD Biosciences, San Jose, CA, USA). Fresh medium containing 10% FBS was added into the lower portion of the chamber. After incubation for 48 h, the cells remaining in the upper chambers were removed. The cells that migrated to the lower surfaces of the wells were fixed with methanol and stained with 0.5% crystal violet. The number of migratory cells was detected using a Zeiss fluorescence photomicroscope and counted based on five randomly chosen visual fields.

Dual luciferase reporter assay

pmirGLO or pmirGLO-DDX17 was co-transfected with SNHG20 overexpression vector or pmirGLO vector (Promega, Madison, WI, USA), named as pmirGLO-DDX17.
SNHG20 knockdown vector into PC3 cells using Lipofectamine 3000 (Invitrogen). After incubation for 48 h, the Firefly luciferase activity and Renilla luciferase activity were measured using the Dual-Luciferase Reporter Assay System (Promega) in accordance with the protocols.

Statistical analysis

GraphPad Prism 5.0 (La Jolla, CA, USA) was used to perform statistical analyses. For comparisons, Wilcoxon signed-rank test, Pearson χ^2 test, one-way ANOVA followed by Dunnett’s multiple comparison tests, Student’s t-test, and Pearson correlation analysis were carried out as indicated. 

Results

Expression level of SNHG20 in human PCa tissues and cell lines

We first analyzed the expression level of SNHG20 in 68 pairs of PCa tissues and adjacent noncancerous tissues by RT-qPCR. The results showed that SNHG20 was markedly increased in PCa tissues compared with adjacent noncancerous tissues (Figure 1 A). Subsequently, we analyzed the relationship between SNHG20 expression level and clinicopathological characteristics in these 68 PCa cases. As shown in Table I, the increased level of SNHG20 was positively associated with high Gleason score and advanced tumor stage. Next, we measured the expression level of SNHG20 in PCa cell lines PC3 and DU145 and the human prostate epithelial cell line RWPE-1 by RT-qPCR. As shown in Figure 1 B, SNHG20 was also markedly increased in PCa cell lines compared with the prostate epithelial cell line.

Enhanced expression of SNHG20 promotes PCa cell proliferation and migration

In order to investigate the roles of SNHG20 in PCa, SNHG20 stably overexpressed and control PC3 and DU145 cells were constructed through the stable transfection of SNHG20 overexpression vector (pcDNA-SNHG20) or control empty vector (pcDNA3.1). The enhanced expression of SNHG20 was verified by RT-qPCR (Figures 2 A and B). CCK-8 assays indicated that enhanced expression of SNHG20 markedly promoted cell proliferation of PC3 and DU145 cells (Figures 2 C and D). EdU incorporation assays further verified that knockdown of SNHG20 significantly repressed cell proliferation of PC3 and DU145 cells (Figures 2 G and H). These data suggested that enhanced expression of SNHG20 promotes PCa cell proliferation and migration.

Knockdown of SNHG20 represses PCa cell proliferation and migration

In order to completely explore the roles of SNHG20 in PCa, SNHG20 stably depleted and control PC3 and DU145 cells were constructed through the stable transfection of SNHG20 knockdown vector (sh-SNHG20) or negative control vector (sh-NC). The knockdown of SNHG20 was verified by RT-qPCR (Figures 3 A and B). CCK-8 assays indicated that knockdown of SNHG20 significantly repressed cell proliferation of PC3 and DU145 cells (Figures 3 C and D). EdU incorporation assays further verified that knockdown of SNHG20 markedly repressed cell proliferation of PC3 and DU145 cells (Figures 3 G and H). Subsequently, we investigated the roles of SNHG20 knockdown on PCa cell migration. Transwell assays revealed that knockdown of SNHG20 significantly repressed cell migration of PC3 and DU145 cells (Figures 3 G and H). These data suggested that knockdown of SNHG20 represses PCa cell proliferation and migration.

SNHG20 upregulates the expression of DDX17

Many lncRNAs were reported to function as ceRNAs to relieve the repressive effects of common miRNAs on their genuine targets [30, 35, 36]. Therefore, we investigated the potential targets which are regulated by DDX17 via the ceRNA mechanism. The potential targets were predicted by starBase (http://starbase.sysu.edu.cn/) and shown in Table II [43]. DDX17 was the top hit, which has 26 shared miRNAs with SNHG20. Furthermore, DDX17 was reported to have oncogenic roles in breast cancer, colon cancer, and non-small cell lung cancer [44–46]. Thus, we further investigated the effects of SNHG20 on DDX17. miRNAs are known to bind the 3′UTR of target genes and repress 3′UTR activity [47–49]. Thus, we first investigated the effects of SNHG20 on DDX17 3′UTR activity. The 3′UTR of DDX17 was cloned into the luciferase reporter pmirGLO. Dual luciferase reporter assays indicated that enhanced expression of SNHG20 significantly increased the luciferase activity of the constructed reporter containing 3′UTR of DDX17 (Figure 4 A). Conversely, knockdown of SNHG20 significantly decreased the luciferase activity of the constructed reporter containing 3′UTR of DDX17 (Figure 4 B). The mRNA and protein expression levels of DDX17 in SNHG20 stably over-
Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17

Table I. The relationship between SNHG20 expression level and clinicopathological characteristics in our PCa cases.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>N (case)</th>
<th>SNHG20</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Age [years]:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 65</td>
<td>26</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>≥ 65</td>
<td>42</td>
<td>19</td>
<td>23</td>
</tr>
<tr>
<td>PSA level [ng/ml]:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 10</td>
<td>15</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>≥ 10</td>
<td>53</td>
<td>24</td>
<td>29</td>
</tr>
<tr>
<td>Gleason score:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 7</td>
<td>38</td>
<td>24</td>
<td>14</td>
</tr>
<tr>
<td>&gt; 7</td>
<td>30</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>Tumor stage:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ T2b</td>
<td>33</td>
<td>22</td>
<td>11</td>
</tr>
<tr>
<td>≥ T2c</td>
<td>35</td>
<td>12</td>
<td>23</td>
</tr>
<tr>
<td>Lymph node metastasis:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>56</td>
<td>31</td>
<td>25</td>
</tr>
<tr>
<td>N1</td>
<td>12</td>
<td>3</td>
<td>9</td>
</tr>
</tbody>
</table>

P-value was acquired by Pearson χ² test.
Figure 2. Enhanced expression of SNHG20 promotes PCa cell proliferation and migration. 

A – The expression level of SNHG20 in SNHG20 stably overexpressed and control PC3 cells was analyzed by RT-qPCR. 

B – The expression level of SNHG20 in SNHG20 stably overexpressed and control DU145 cells was analyzed by RT-qPCR. 

C – Cell proliferation of SNHG20 stably overexpressed and control PC3 cells was detected by CCK-8 assays. OD values in 450 nm at indicated time points were collected to indicate cell proliferation. 

D – Cell proliferation of SNHG20 stably overexpressed and control DU145 cells was detected by CCK-8 assays. OD values in 450 nm at indicated time points were collected to indicate cell proliferation. 

E – Cell proliferation of SNHG20 stably overexpressed and control PC3 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. 

F – Cell proliferation of SNHG20 stably overexpressed and control DU145 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. 

G – Cell migration of SNHG20 stably overexpressed and control PC3 cells was detected by transwell assays. Scale bars, 100 μm. 

H – Cell migration of SNHG20 stably overexpressed and control DU145 cells was detected by transwell assays. Scale bars, 100 μm. 

Results are presented as mean ± SD. **p < 0.01, ***p < 0.001 compared with pcDNA3.1 group by Student’s t-test.
Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17

Figure 3. Knockdown of SNHG20 represses PCa cell proliferation and migration. A – The expression level of SNHG20 in SNHG20 stably depleted and control PC3 cells was analyzed by RT-qPCR. B – The expression level of SNHG20 in SNHG20 stably depleted and control DU145 cells was analyzed by RT-qPCR. C – Cell proliferation of SNHG20 stably depleted and control PC3 cells was detected by CCK-8 assays. OD values in 450 nm at indicated time points were collected to indicate cell proliferation. D – Cell proliferation of SNHG20 stably depleted and control DU145 cells was detected by CCK-8 assays. OD values in 450 nm at indicated time points were collected to indicate cell proliferation. E – Cell proliferation of SNHG20 stably depleted and control PC3 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. F – Cell proliferation of SNHG20 stably depleted and control DU145 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. G – Cell migration of SNHG20 stably depleted and control PC3 cells was detected by transwell assays. Scale bars, 100 μm. H – Cell migration of SNHG20 stably depleted and control DU145 cells was detected by transwell assays. Scale bars, 100 μm. Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 compared with sh-NC group by Student’s t-test.
expressed and depleted PC3 cells were detected by RT-qPCR and western blot, respectively. As displayed in Figures 4 C and D, enhanced expression of SNHG20 upregulated DDX17 mRNA level, while knockdown of SNHG20 downregulated DDX17 mRNA level. Furthermore, enhanced expression of SNHG20 also increased DDX17 protein level, while knockdown of SNHG20 decreased DDX17 protein level (Figures 4 E and F). Taken together, these data suggested that SNHG20 upregulates the expression of DDX17 via the ceRNA mechanism. 

Expression level of DDX17 is positively associated with that of SNHG20 in human PCA tissues

Next, the mRNA and protein levels of SNHG20 in PCA cell lines PC3 and DU145 and the human prostate epithelial cell line RWPE-1 were measured by RT-qPCR and western blot. As shown in Figures 5 A and B, consistent with SNHG20, DDX17 mRNA and protein levels were also markedly increased in PCA cell lines compared with the prostate epithelial cell line. In order to verify whether the positive regulation of DDX17 by SNHG20 exists in vivo, the mRNA level of DDX17 in the same 68 pairs of PCA tissues and adjacent noncancerous tissues used in Figure 1 was detected by RT-qPCR. As shown in Figure 5 C, DDX17 was also significantly increased in PCA tissues compared with adjacent noncancerous tissues. We further analyzed the correlation between the expression level of DDX17 and that of SNHG20 in these 68 PCA tissues. As shown in Figure 5 D, the RNA level of DDX17 was significantly positively associated with that of SNHG20 in PCA tissues ($r = 0.7331$, $p < 0.0001$).

**DDX17 promotes PCA cell proliferation and migration**

Although DDX17 has been reported to have oncogenic roles in breast cancer, colon cancer, and non-small cell lung cancer, the biological roles of DDX17 in PCA are still unclear. Thus, we further investigated the roles of DDX17 in PCA cell proliferation and migration. DDX17 stably overexpressed and control PC3 cells were constructed through the stable transfection of DDX17 overexpression vector or control empty vector. The enhanced expression of DDX17 was verified by western blot (Figure 6 A). CCK-8 assays indicated that enhanced expression of DDX17 markedly promoted cell proliferation of PC3 cells (Figure 6 B). EdU incorporation assays further verified that enhanced expression of DDX17 markedly promoted cell proliferation of PC3 cells (Figure 6 C). Subsequently, we investigated the roles of DDX17 in PCA cell migration. Transwell assays revealed that enhanced expression of DDX17 significantly promoted cell migration of PC3 cells (Figure 6 D). These results demonstrated that DDX17 also has oncogenic roles in PCA.

<table>
<thead>
<tr>
<th>ceRNA name</th>
<th>Gene ID</th>
<th>Gene name</th>
<th>Gene type</th>
<th>Hit MIR num</th>
<th>P-value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNHG20</td>
<td>ENSG00000100201</td>
<td>DDX17</td>
<td>Protein_coding</td>
<td>26</td>
<td>2.80E-04</td>
<td>4.63E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000011021</td>
<td>CLCN6</td>
<td>Protein_coding</td>
<td>25</td>
<td>1.60E-03</td>
<td>1.60E-03</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG000000128487</td>
<td>SPECC1</td>
<td>Protein_coding</td>
<td>24</td>
<td>1.05E-04</td>
<td>2.64E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000080815</td>
<td>PSEN1</td>
<td>Protein_coding</td>
<td>22</td>
<td>9.10E-04</td>
<td>1.05E-03</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000155858</td>
<td>LSM11</td>
<td>Protein_coding</td>
<td>21</td>
<td>7.26E-04</td>
<td>4.63E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG000001200071</td>
<td>KANSL1</td>
<td>Protein_coding</td>
<td>20</td>
<td>1.21E-03</td>
<td>1.30E-03</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000158805</td>
<td>ZNF276</td>
<td>Protein_coding</td>
<td>19</td>
<td>5.69E-05</td>
<td>2.64E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000116852</td>
<td>KIF21B</td>
<td>Protein_coding</td>
<td>19</td>
<td>6.18E-04</td>
<td>7.73E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000157851</td>
<td>DPYSL5</td>
<td>Protein_coding</td>
<td>16</td>
<td>5.43E-04</td>
<td>7.40E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000213352</td>
<td>GAPDH44</td>
<td>Processed_pseudogene</td>
<td>13</td>
<td>1.29E-06</td>
<td>1.93E-05</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG000000101298</td>
<td>SNPH</td>
<td>Protein_coding</td>
<td>13</td>
<td>6.20E-05</td>
<td>2.64E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000126368</td>
<td>NR1D1</td>
<td>Protein_coding</td>
<td>10</td>
<td>5.28E-05</td>
<td>2.64E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000230593</td>
<td>PPIAP40</td>
<td>Processed_pseudogene</td>
<td>8</td>
<td>1.02E-04</td>
<td>2.64E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000213226</td>
<td>AC242426.1</td>
<td>Processed_pseudogene</td>
<td>7</td>
<td>3.19E-05</td>
<td>2.39E-04</td>
</tr>
<tr>
<td>SNHG20</td>
<td>ENSG00000203650</td>
<td>LINC01285</td>
<td>LincRNA</td>
<td>5</td>
<td>1.39E-04</td>
<td>2.64E-04</td>
</tr>
</tbody>
</table>
Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17

Figure 4. SNHG20 upregulates the expression of DDX17. A – Luciferase activity in PC3 cells co-transfected with luciferase reporters containing DDX17 3′UTR or nothing and SNHG20 overexpression vector (pcDNA-SNHG20) or control empty vector (pcDNA3.1). Results are displayed as the relative ratio of firefly luciferase activity to Renilla luciferase activity. B – Luciferase activity in PC3 cells co-transfected with luciferase reporters containing DDX17 3′UTR or nothing and SNHG20 knockdown vector (sh-SNHG20) or negative control vector (sh-NC). Results are displayed as the relative ratio of firefly luciferase activity to Renilla luciferase activity. C – The mRNA level of DDX17 in SNHG20 stably overexpressed and control PC3 cells was analyzed by RT-qPCR. D – The mRNA level of DDX17 in SNHG20 stably depleted and control PC3 cells was analyzed by RT-qPCR. E – The protein level of DDX17 in SNHG20 stably overexpressed and control PC3 cells was analyzed by western blot. F – The protein level of DDX17 in SNHG20 stably depleted and control PC3 cells was analyzed by western blot.

Depletion of DDX17 reverses the roles of SNHG20 in promoting PCa cell proliferation and migration

To verify whether SNHG20 promotes PCa cell proliferation and migration via the upregulation of DDX17, we stably depleted DDX17 in SNHG20 stably overexpressed PC-3 cells via the stable transfection of DDX17 knockdown vector (sh-DDX17). The knockdown of DDX17 was verified by western blot (Figure 7 A). CCK-8 assays indicated that knockdown of DDX17 attenuated the pro-proliferative roles of SNHG20 overexpression (Figure 7 B). EdU incorporation assays further verified that knockdown of DDX17 reversed the pro-proliferative roles of SNHG20 overexpression (Figure 7 C). Transwell assays revealed that knockdown of DDX17 attenuated the pro-migratory roles of SNHG20 overexpression (Figure 7 D). These results demonstrated that knockdown of DDX17 reverses the roles of SNHG20 in promoting PCa cell proliferation and migration.

Discussion

As a class of novel regulatory RNAs, lncRNAs are revealed to have various roles in PCa [50–54]. LncRNA TMPO-AS1 is reported to promote PCa cell proliferation and migration [50]. DDX5/p68 associated lncRNA LOC284454 is reduced in PCa [51]. LncRNA LINC00844 prevents PCa cell migration...
and invasion via facilitating androgen receptor binding to the chromatin [52]. LncRNA MIR222HG facilitates PCA development via affecting miRNAs-mediated expression silencing [53]. LncRNA SCHLAP1 promotes aggressive PCA via antagonizing the SWI/SNF complex [54]. Due to the huge number of lncRNAs in humans, other lncRNAs may also play important roles in PCa. In the present study, we identified lncRNA SNHG20 as a novel oncogene in PCa. Our data revealed that SNHG20 is highly expressed in PCa tissues and cell lines compared with adjacent noncancerous tissues and the prostate epithelial cell line, respectively. Moreover, we revealed that high expression of SNHG20 is positively associated with high Gleason score and advanced tumor stages. Gain-of-function and loss-of-function experiments revealed that enhanced expression of SNHG20 promotes PCA cell proliferation and migration, while knockdown of SNHG20 represses PCA cell proliferation and migration. Therefore, our data suggested that SNHG20 acts as an oncogene in PCA.

Several lncRNAs have been verified to function as ceRNAs via competitively binding common miRNAs [35, 36, 41]. Thus, we further explored the potential of SNHG20 acting as a ceRNA in PCa. Using starBase, we objectively screened all the targets which share common miRNAs with SNHG20. DDX17 was identified to share 26 common miRNAs with SNHG20. In clinical samples, we further found that consistent with SNHG20, DDX17 was also highly expressed in PCa tissues. In addition, the expression of DDX17 was significantly positively associated with that of SNHG20 in PCa tissues, which further supports the potential regulation of DDX17 by SNHG20. Indeed, dual luciferase reporter assays, RT-qPCR, and western blot experiments all verified that SNHG20 increased 3’UTR activity, mRNA level, and protein level of DDX17 in PCa cells, which

Figure 5. The relationship between SNHG20 and DDX17 expression levels in PCa tissues. A – DDX17 mRNA level in human prostate epithelial cell line RWPE-1 and PCa cell lines PC3 and DU145 was analyzed by RT-qPCR. Results are presented as mean ± SD. ***p < 0.001 compared with RWPE-1 group by one-way ANOVA followed by Dunnett’s multiple comparison tests. B – DDX17 protein level in human prostate epithelial cell line RWPE-1 and PCa cell lines PC3 and DU145 was analyzed by western blot. C – DDX17 mRNA level in 68 pairs of PCa tissues and adjacent noncancerous tissues was analyzed by RT-qPCR. Results are displayed as median with interquartile range. ***p < 0.0001 by Wilcoxon signed-rank test. D – The correlation between DDX17 and SNHG20 expression level in PCa tissues was analyzed by Pearson correlation analysis. n = 68, r = 0.7331, p < 0.0001
Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17

Figure 6. DDX17 promotes PCa cell proliferation and migration. A – The expression level of DDX17 in DDX17 stably overexpressed and control PC3 cells was analyzed by western blot. B – Cell proliferation of DDX17 stably overexpressed and control PC3 cells was detected by CCK-8 assays. OD values at 450 nm at indicated time points were collected to indicate cell proliferation. C – Cell proliferation of DDX17 stably overexpressed and control PC3 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. D – Cell migration of DDX17 stably overexpressed and control PC3 cells was detected by transwell assays. Scale bars, 100 μm. Results are presented as mean ± SD. **p < 0.01 compared with control group by Student’s t-test.

DDX17 promotes PCa cell proliferation and migration. Moreover, depletion of DDX17 reverses the roles of SNHG20 in promoting PCa cell proliferation and migration. These data suggest that the up-regulation of DDX17 at least partially mediates the oncogenic roles of SNHG20 in PCa. Further exploration of the downstream targets of SNHG20/DDX17 would promote better understanding of the mechanisms of action of SNHG20.

In conclusion, collectively, our results show that IncRNA SNHG20 is highly expressed in PCa and associated with advanced tumor stages. SNHG20 promotes PCa cell proliferation and migration via acting as a ceRNA and further upregulating DDX17. Our data imply that SNHG20 may be a novel potential therapeutic target for PCa.

Conflict of interest

The authors declare no conflict of interest.
Figure 7. Depletion of DDX17 reverses the roles of SNHG20 in promoting PCa cell proliferation and migration. 
A – The expression level of DDX17 in SNHG20 stably overexpressed and concurrently DDX17 stably depleted PC3 cells was analyzed by western blot. B – Cell proliferation of SNHG20 stably overexpressed and concurrently DDX17 stably depleted PC3 cells was detected by CCK-8 assays. OD values in 450 nm at indicated time points were collected to indicate cell proliferation. C – Cell proliferation of SNHG20 stably overexpressed and concurrently DDX17 stably depleted PC3 cells was detected by EdU incorporation assays. Red color indicates EdU-positive cells. Scale bars, 100 μm. D – Cell migration of SNHG20 stably overexpressed and concurrently DDX17 stably depleted PC3 cells was detected by transwell assays. Scale bars, 100 μm.

Results are presented as mean ± SD. *p < 0.05, ***p < 0.001 compared with pcDNA3.1 + sh-NC group by one-way ANOVA followed by Dunnett’s multiple comparison tests.

References


